Cargando…
A Hot Topic: Cancer Immunotherapy and Natural Killer Cells
Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them ha...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776043/ https://www.ncbi.nlm.nih.gov/pubmed/35054985 http://dx.doi.org/10.3390/ijms23020797 |
_version_ | 1784636735176572928 |
---|---|
author | Michel, Tatiana Ollert, Markus Zimmer, Jacques |
author_facet | Michel, Tatiana Ollert, Markus Zimmer, Jacques |
author_sort | Michel, Tatiana |
collection | PubMed |
description | Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them have already been successfully introduced into the clinic. Among these, immunotherapy based on natural killer (NK) cells is considered as one of the most promising options. In the present review, we will expose the different possibilities NK cells offer in this context, compare data about the theoretical background and mechanism(s) of action, report some results of clinical trials and identify several very recent trends. The pharmaceutical industry is quite interested in NK cell immunotherapy, which will benefit the speed of progress in the field. |
format | Online Article Text |
id | pubmed-8776043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87760432022-01-21 A Hot Topic: Cancer Immunotherapy and Natural Killer Cells Michel, Tatiana Ollert, Markus Zimmer, Jacques Int J Mol Sci Review Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them have already been successfully introduced into the clinic. Among these, immunotherapy based on natural killer (NK) cells is considered as one of the most promising options. In the present review, we will expose the different possibilities NK cells offer in this context, compare data about the theoretical background and mechanism(s) of action, report some results of clinical trials and identify several very recent trends. The pharmaceutical industry is quite interested in NK cell immunotherapy, which will benefit the speed of progress in the field. MDPI 2022-01-12 /pmc/articles/PMC8776043/ /pubmed/35054985 http://dx.doi.org/10.3390/ijms23020797 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Michel, Tatiana Ollert, Markus Zimmer, Jacques A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title | A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title_full | A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title_fullStr | A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title_full_unstemmed | A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title_short | A Hot Topic: Cancer Immunotherapy and Natural Killer Cells |
title_sort | hot topic: cancer immunotherapy and natural killer cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776043/ https://www.ncbi.nlm.nih.gov/pubmed/35054985 http://dx.doi.org/10.3390/ijms23020797 |
work_keys_str_mv | AT micheltatiana ahottopiccancerimmunotherapyandnaturalkillercells AT ollertmarkus ahottopiccancerimmunotherapyandnaturalkillercells AT zimmerjacques ahottopiccancerimmunotherapyandnaturalkillercells AT micheltatiana hottopiccancerimmunotherapyandnaturalkillercells AT ollertmarkus hottopiccancerimmunotherapyandnaturalkillercells AT zimmerjacques hottopiccancerimmunotherapyandnaturalkillercells |